Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21Current Group expectations for FY/21 Based on the current status of the Group's financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth1 and at least broadly stable net income2 year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care's results and hence on Fresenius Group's net income2 growth.
Group medium-term targets The current information and assumptions do not trigger a revision of Fresenius' medium-term growth targets, which were set before the COVID-19 pandemic emerged.
Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.
1 in constant currency2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programs
For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.
Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board
Bad Homburg v.d.H., February 1, 2021
Contact: Markus Georgi Senior Vice President Investor Relations & Sustainability T: +49 (0) 6172 608-2485 firstname.lastname@example.org
End of Note
01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Fresenius SE & Co. KGaA Else-Kr?ner-Stra?e 1 61352 Bad Homburg v.d.H.
Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: email@example.com Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange EQS News ID: 1164992 ? End of Announcement DGAP News Service